Drugs Made In America Acquisition II (DMII) Fundamentals 2026 — P/E 0.6x, Revenue Analysis | SniperIQ
Drugs Made In America Acquisition II (DMII) is a US-listed Financial Services company in Shell Companies with a market capitalization of $530M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Drugs Made In America Acquisition II's market cap?
Drugs Made In America Acquisition II (DMII) has a market capitalization of approximately $530M, trading at
What is Drugs Made In America Acquisition II's P/E ratio?
Drugs Made In America Acquisition II's trailing twelve-month P/E ratio is 0.6x, with a price-to-book (P/B) of 0.0x. Valuation multiples are best compared with Financial Services sector peers rather than read in isolation.
How profitable is Drugs Made In America Acquisition II?
Drugs Made In America Acquisition II runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Drugs Made In America Acquisition II pay a dividend?
Drugs Made In America Acquisition II does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Drugs Made In America Acquisition II financially healthy?
Drugs Made In America Acquisition II carries a debt-to-equity ratio of 0.00x and a current ratio of 0.53x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Drugs Made In America Acquisition II a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Drugs Made In America Acquisition II (DMII) the key facts are: market cap $530M, P/E 0.6x, 52-week range 9.86-10.11. Weigh valuation, profitability, growth, and balance-sheet strength against Financial Services peers and form your own view.
Track Drugs Made In America Acquisition II's full fundamentals live
Get Drugs Made In America Acquisition II's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.